Anika Therapeutics Stock Price, News & Analysis (NASDAQ:ANIK)

$51.69 -6.02 (-10.43 %)
(As of 02/25/2018 12:41 PM ET)
Previous Close$51.69
Today's Range$45.74 - $52.46
52-Week Range$41.64 - $69.81
Volume263,059 shs
Average Volume99,862 shs
Market Capitalization$759.22 million
P/E Ratio24.38
Dividend YieldN/A
Beta1.6

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Debt-to-Equity RatioN/A
Current Ratio15.79%
Quick Ratio15.28%

Price-To-Earnings

Trailing P/E Ratio24.3821904820306
Forward P/E Ratio32.31
P/E Growth3.13

Sales & Book Value

Annual Sales$113.42 million
Price / Sales6.69
Cash Flow$2.48 per share
Price / Cash20.84
Book Value$17.94 per share
Price / Book2.88

Profitability

Trailing EPS$2.12
Net Income$32.54 million
Net Margins28.05%
Return on Equity11.91%
Return on Assets11.05%

Miscellaneous

Employees122
Outstanding Shares14,690,000

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) released its quarterly earnings results on Wednesday, February, 21st. The biotechnology company reported $0.38 earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by $0.03. The biotechnology company had revenue of $29.39 million for the quarter, compared to analysts' expectations of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.54 earnings per share. View Anika Therapeutics' Earnings History.

When will Anika Therapeutics make its next earnings announcement?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Anika Therapeutics.

Where is Anika Therapeutics' stock going? Where will Anika Therapeutics' stock price be in 2018?

3 brokerages have issued 12 month target prices for Anika Therapeutics' shares. Their forecasts range from $57.00 to $68.00. On average, they anticipate Anika Therapeutics' share price to reach $62.50 in the next year. View Analyst Ratings for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

  • Joseph G. Darling, President (Age 59)
  • Charles H. Sherwood Ph.D., Chief Executive Officer, Director (Age 70)
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary (Age 42)
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer (Age 45)
  • Richard Hague, Chief Commercial Officer (Age 57)
  • Joseph Lyon Bower Ph.D., Lead Independent Director (Age 79)
  • Raymond J. Land, Independent Director (Age 72)
  • Glenn R. Larsen Ph.D., Independent Director (Age 62)
  • Jeffrey S. Thompson, Independent Director (Age 51)
  • Steven E. Wheeler, Independent Director (Age 70)

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.80%), Bank of New York Mellon Corp (3.60%), AMI Asset Management Corp (1.88%), BTIM Corp. (1.71%), Thomson Horstmann & Bryant Inc. (1.66%) and Wells Fargo & Company MN (1.47%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?

Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Two Sigma Advisers LP, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Gotham Asset Management LLC, BTIM Corp., AMI Asset Management Corp and Metropolitan Life Insurance Co. NY. Company insiders that have sold Anika Therapeutics company stock in the last year include Charles H Sherwood, Jeffery S Thompson and Richard Hague. View Insider Buying and Selling for Anika Therapeutics.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Thomson Horstmann & Bryant Inc., Hussman Strategic Advisors Inc., Deutsche Bank AG, Arizona State Retirement System, Creative Planning, Pinebridge Investments L.P. and Stone Ridge Asset Management LLC. View Insider Buying and Selling for Anika Therapeutics.

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of Anika Therapeutics stock can currently be purchased for approximately $51.69.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $759.22 million and generates $113.42 million in revenue each year. The biotechnology company earns $32.54 million in net income (profit) each year or $2.12 on an earnings per share basis. Anika Therapeutics employs 122 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (ANIK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anika Therapeutics (NASDAQ:ANIK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.673.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.50$62.50$57.00N/A
Price Target Upside: 8.30% upside8.02% downside3.92% upsideN/A

Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History

Price Target History for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Barrington ResearchDowngradeOutperform -> Market PerformHighView Rating Details
1/26/2018SidotiInitiated CoverageBuyLowView Rating Details
1/24/2018First AnalysisUpgradeEqual Weight -> Overweight$45.00 -> $68.00HighView Rating Details
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Anika Therapeutics (NASDAQ:ANIK) Earnings History and Estimates Chart

Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018$0.32N/AView Earnings Details
2/21/2018Q4 2017$0.41$0.38$29.85 million$29.39 millionViewListenView Earnings Details
10/25/2017Q3 2017$0.41$0.46$27.44 million$27.18 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.44$0.76$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.38$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.17$0.21$15.54 million$15.25 millionViewN/AView Earnings Details
2/27/2013Q4 2012$0.23$0.42ViewN/AView Earnings Details
10/30/2012Q3 2012$0.16$0.11ViewN/AView Earnings Details
8/1/2012Q2 2012$0.26ViewN/AView Earnings Details
5/3/2012Q1 2012$0.14ViewN/AView Earnings Details
2/29/2012Q4 2011$0.21ViewN/AView Earnings Details
11/2/2011Q3 2011$0.22ViewN/AView Earnings Details
8/4/2011Q2 2011$0.17ViewN/AView Earnings Details
5/4/2011Q1 2011$0.02ViewN/AView Earnings Details
3/9/2011Q4 2010$0.10ViewN/AView Earnings Details
11/8/2010Q3 2010$0.09ViewN/AView Earnings Details
8/9/2010Q2 2010$0.08ViewN/AView Earnings Details
5/10/2010Q1 2010$0.05ViewN/AView Earnings Details
3/16/2010Q4 2009$0.17ViewN/AView Earnings Details
10/27/2009Q3 2009$0.10$0.13ViewN/AView Earnings Details
7/22/2009Q2 2009$0.08$0.08ViewN/AView Earnings Details
4/28/2009Q1 2009$0.09$0.05ViewN/AView Earnings Details
3/5/2009Q4 2008$0.13$0.10ViewN/AView Earnings Details
11/3/2008Q3 2008$0.12$0.10ViewN/AView Earnings Details
7/22/2008Q2 2008$0.05$0.07ViewN/AView Earnings Details
4/30/2008Q1 2008$0.08$0.05ViewN/AView Earnings Details
3/5/2008Q4 2007$0.13$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Anika Therapeutics (NASDAQ:ANIK) Earnings Estimates

2018 EPS Consensus Estimate: $1.62
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.26$0.28$0.27
Q2 20182$0.41$0.46$0.44
Q3 20182$0.37$0.45$0.41
Q4 20181$0.50$0.50$0.50
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Anika Therapeutics (NASDAQ:ANIK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 85.29%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Richard HagueInsiderSell5,250$54.48$286,020.00View SEC Filing  
10/23/2017Charles H SherwoodCEOSell22,228$60.06$1,335,013.68158,297View SEC Filing  
10/20/2017Charles H SherwoodCEOSell5,991$60.04$359,699.64158,297View SEC Filing  
10/16/2017Charles H SherwoodCEOSell3,293$60.04$197,711.72View SEC Filing  
10/13/2017Charles H SherwoodCEOSell7,124$60.08$428,009.92View SEC Filing  
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21174,705View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03246,740View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.7515,845View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.6038,513View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.9014,165View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anika Therapeutics (NASDAQ ANIK) News Headlines

Source:
DateHeadline
Anika Therapeutics (ANIK) Lowered to Hold at BidaskClubAnika Therapeutics (ANIK) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 24 at 3:52 PM
Anika Therapeutics (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAnika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 24 at 8:30 AM
Anika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - BenzingaAnika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - Benzinga
www.benzinga.com - February 24 at 8:30 AM
Kamada (KMDA) and Anika Therapeutics (ANIK) Critical SurveyKamada (KMDA) and Anika Therapeutics (ANIK) Critical Survey
www.americanbankingnews.com - February 24 at 1:06 AM
Anika Therapeutics Shares Stunted By Increased Investment, Barrington Says In DowngradeAnika Therapeutics Shares Stunted By Increased Investment, Barrington Says In Downgrade
finance.yahoo.com - February 23 at 5:42 PM
Anika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington ResearchAnika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington Research
www.americanbankingnews.com - February 23 at 4:28 PM
Anika Therapeutics Inc. 2017 Q4 - Results - Earnings Call SlidesAnika Therapeutics Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 22 at 5:27 PM
Anika Therapeutics (ANIK) Releases  Earnings Results, Misses Expectations By $0.03 EPSAnika Therapeutics (ANIK) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - February 22 at 3:26 PM
Anika Reports Fourth Quarter and Full Year 2017 Financial ResultsAnika Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 21 at 5:17 PM
When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)?When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)?
finance.yahoo.com - February 21 at 5:17 PM
Zacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 18 at 3:14 AM
Anika Therapeutics (ANIK) Set to Announce Earnings on WednesdayAnika Therapeutics (ANIK) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 14 at 4:32 AM
Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
finance.yahoo.com - February 8 at 8:21 AM
Anika Therapeutics (ANIK) to Release Earnings on TuesdayAnika Therapeutics (ANIK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 6 at 3:12 AM
 Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK) Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 3 at 3:26 AM
Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for OsteoarthritisAnika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
finance.yahoo.com - February 2 at 9:46 AM
First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"
www.americanbankingnews.com - January 28 at 6:36 PM
Anika Therapeutics (ANIK) Lifted to Buy at BidaskClubAnika Therapeutics (ANIK) Lifted to Buy at BidaskClub
www.americanbankingnews.com - January 27 at 10:16 AM
Sidoti Initiates Coverage on Anika Therapeutics (ANIK)Sidoti Initiates Coverage on Anika Therapeutics (ANIK)
www.americanbankingnews.com - January 26 at 4:54 PM
First Analysis Weighs in on Anika Therapeutics Incs Q4 2017 Earnings (ANIK)First Analysis Weighs in on Anika Therapeutics Inc's Q4 2017 Earnings (ANIK)
www.americanbankingnews.com - January 26 at 6:46 AM
Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid ArthritisAnika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
finance.yahoo.com - January 25 at 9:46 AM
First Analysis Weighs in on Anika Therapeutics Incs FY2017 Earnings (ANIK)First Analysis Weighs in on Anika Therapeutics Inc's FY2017 Earnings (ANIK)
www.americanbankingnews.com - January 25 at 7:58 AM
Recent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - January 22 at 9:22 AM
 Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK) Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)
www.americanbankingnews.com - January 19 at 3:58 AM
Anika Therapeutics (ANIK) and 3SBio (SSRX) Head to Head AnalysisAnika Therapeutics (ANIK) and 3SBio (SSRX) Head to Head Analysis
www.americanbankingnews.com - January 6 at 1:36 PM
 Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Brokerages Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 4 at 2:00 AM
Optimer Pharmaceuticals (OPTR) and Anika Therapeutics (ANIK) Financial AnalysisOptimer Pharmaceuticals (OPTR) and Anika Therapeutics (ANIK) Financial Analysis
www.americanbankingnews.com - January 2 at 5:12 PM
 Anika Therapeutics Inc. (ANIK) Receives Consensus Recommendation of "Strong Buy" from Brokerages Anika Therapeutics Inc. (ANIK) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 30 at 9:40 PM
Anika Therapeutics (ANIK) Buy Rating Reiterated at Barrington ResearchAnika Therapeutics' (ANIK) Buy Rating Reiterated at Barrington Research
www.americanbankingnews.com - December 29 at 1:26 PM
Anika Therapeutics (ANIK) Upgraded at BidaskClubAnika Therapeutics (ANIK) Upgraded at BidaskClub
www.americanbankingnews.com - December 28 at 8:42 PM
Analyst: Dont Expect Anikas Latest FDA Cleared Treatment To Impact 2018Analyst: Don't Expect Anika's Latest FDA Cleared Treatment To Impact 2018
finance.yahoo.com - December 28 at 4:30 PM
Anika Therapeutics (ANIK) Announces HA-Based Bone Void Filer Receives FDA 510(k) ClearanceAnika Therapeutics (ANIK) Announces HA-Based Bone Void Filer Receives FDA 510(k) Clearance
www.streetinsider.com - December 27 at 8:11 PM
Hovnanian and Kindred climb while Callaway Golf slumpsHovnanian and Kindred climb while Callaway Golf slumps
marketbeat.com - December 27 at 5:13 PM
 Anika Therapeutics Inc. (ANIK) Given Average Recommendation of "Strong Buy" by Analysts Anika Therapeutics Inc. (ANIK) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 27 at 4:32 PM
BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair TreatmentBRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment
www.reuters.com - December 27 at 9:13 AM
Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair TreatmentAnika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment
finance.yahoo.com - December 27 at 9:12 AM
ETFs with exposure to Anika Therapeutics, Inc. : December 25, 2017ETFs with exposure to Anika Therapeutics, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 3:57 PM
BidaskClub Lowers Anika Therapeutics (ANIK) to SellBidaskClub Lowers Anika Therapeutics (ANIK) to Sell
www.americanbankingnews.com - December 17 at 7:44 AM
Anika Therapeutics (ANIK) & Argos Therapeutics (ARGS) Head-To-Head ContrastAnika Therapeutics (ANIK) & Argos Therapeutics (ARGS) Head-To-Head Contrast
www.americanbankingnews.com - December 15 at 5:52 AM
7 Quality Stocks With High Business Predictability Ratings7 Quality Stocks With High Business Predictability Ratings
finance.yahoo.com - December 14 at 3:22 PM
Reviewing Ambit Biosciences (AMBI) & Anika Therapeutics (ANIK)Reviewing Ambit Biosciences (AMBI) & Anika Therapeutics (ANIK)
www.americanbankingnews.com - December 14 at 10:06 AM
ETFs with exposure to Anika Therapeutics, Inc. : December 13, 2017ETFs with exposure to Anika Therapeutics, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 3:22 PM
Zacks: Brokerages Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)Zacks: Brokerages Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)
www.americanbankingnews.com - December 11 at 5:56 AM
Brokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.54 EPSBrokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.54 EPS
www.americanbankingnews.com - December 7 at 8:34 AM
Anika Therapeutics (ANIK) and Biogen (BIIB) Financial ComparisonAnika Therapeutics (ANIK) and Biogen (BIIB) Financial Comparison
www.americanbankingnews.com - December 6 at 11:20 AM
Anika Therapeutics Inc. (ANIK) Insider Richard Hague Sells 5,250 SharesAnika Therapeutics Inc. (ANIK) Insider Richard Hague Sells 5,250 Shares
www.americanbankingnews.com - December 1 at 9:50 PM
ETFs with exposure to Anika Therapeutics, Inc. : November 27, 2017ETFs with exposure to Anika Therapeutics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:18 PM
Anika Therapeutics (ANIK) and Trius Therapeutics (TSRX) Head to Head ComparisonAnika Therapeutics (ANIK) and Trius Therapeutics (TSRX) Head to Head Comparison
www.americanbankingnews.com - November 22 at 5:24 PM
Anika Therapeutics (ANIK) & Auxilium Pharmaceuticals (AUXL) Financial SurveyAnika Therapeutics (ANIK) & Auxilium Pharmaceuticals (AUXL) Financial Survey
www.americanbankingnews.com - November 22 at 3:42 PM
Analysts Expect Anika Therapeutics Inc. (ANIK) to Announce $0.54 Earnings Per ShareAnalysts Expect Anika Therapeutics Inc. (ANIK) to Announce $0.54 Earnings Per Share
www.americanbankingnews.com - November 21 at 11:42 AM

SEC Filings

Anika Therapeutics (NASDAQ:ANIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anika Therapeutics (NASDAQ ANIK) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.